Clinical Trial

PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Single-center, Single-arm Clinical Trial on the Safety and Efficacy of PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Stage IIIA Non-Small Cell Lung Cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-21.
Trial Details
NCT Number NCT07043907
Lead Sponsor Shenzhen Celconta Life Science Co., Ltd.
Conditions Stage IIIA Non-small Cell Lung Cancer
Enrollment 115 participants
Start Date 2025-07-08
Primary Completion 2028-07-08 (estimated)
Study Completion 2029-06-18 (estimated)
Updated on ClinicalTrials.gov 2025-07-01